LLYEli Lilly and CompanyRunning, no new patients
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
Metastatic Non-Small Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 545 (final count)
- Started
- May 6, 2015
- Main results expected
- Jan 23, 2019
- Fully finished
- Dec 2026
- Results posted
- Mar 4, 2020
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part B: Progression Free Survival (PFS)
Measured over: Randomization to Measured Progressive Disease or Death from Any Cause (Up To 37 Months)
Number of Participants With Treatment-Emergent Adverse Events
Measured over: Cycle 1 Day 1 through End of Study (Up To 3 Years)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT02411448 · record last updated 2026-10-06 · checked 2026-11-09 15:36 UTC